Department of Family Medicine, Chest Medicine, Geriatric Medicine and Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan.
College of Medicine, China Medical University, Taichung, Taiwan.
Eur J Med Res. 2024 Apr 22;29(1):245. doi: 10.1186/s40001-024-01836-1.
To determine the effect of colchicine on cancer risk in patients with the immune-mediated inflammatory diseases (IMIDs)-related to colchicine use.
This is a time-dependent propensity-matched general population study based on the National Health Insurance Research Database (NHIRD) of Taiwan. We identified the IMIDs patients (n = 111,644) newly diagnosed between 2000 and 2012 based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)-274,712, 135, 136.1, 279.49, 518.3, 287.0, 696.0, 696.1, 696.8, 420, 429.4, 710.0, 710.1, 710.3, 710.4, 714.0, 720, 55.0, 55.1, 55.9, 556.
aged ≧ 20 years, if a patient had at least these disease diagnosis requirements within 1 year of follow-up, and, these patients had at least two outpatient visits or an inpatient visit. After propensity-matched according to age, sex, comorbidities, medications and index date, the IMIDs patients enter into colchicine users (N = 16,026) and colchicine nonusers (N = 16,026). Furthermore, time-dependent Cox models were used to analyze cancer risk in propensity-matched colchicine users compared with the nonusers. The cumulative cancer incidence was analyzed using Cox proportional regression analysis. We calculated adjusted hazard ratios (aHRs) and their 95% confidence intervals (95% CIs) for cancer after adjusting for sex, age, comorbidities, and use of medicine including acetylcysteine, medication for smoking cessation such as nicotine replacement medicines (the nicotine patch) and pill medicines (varenicline), anti-inflammatory drugs and immunosuppressant drugs.
Comparing the colchicine nonusers, all cancer risk were mildly attenuated, the (aHR (95% CI)) of all cancer is (0.84 (0.55, 0.99)). Meanwhile, the colchicine users were associated with the lower incidence of the colorectal cancer, the (aHRs (95% CI)) is (0.22 (0.19, 0.89)). Those aged < 65 years and male/female having the colchicine users were associated with lower risk the colorectal cancer also. Moreover, the colchicine > 20 days use with the lower aHR for colorectal cancer.
Colchicine was associated with the lower aHR of the all cancer and colorectal cancer formation in patients with the IMIDs.
为了确定秋水仙碱对与秋水仙碱使用相关的免疫介导的炎症性疾病（IMIDs）患者癌症风险的影响。
这是一项基于台湾全民健康保险研究数据库（NHIRD）的时间依赖性倾向匹配的一般人群研究。我们根据国际疾病分类，第 9 修订版，临床修正（ICD-9-CM）-274,712、135、136.1、279.49、518.3、287.0、696.0、696.1、696.8、420、429.4、710.0、710.1、710.3、710.4、714.0、720、55.0、55.1、55.9、556.，确定了 2000 年至 2012 年间新诊断的 IMIDs 患者（n=111644）。
年龄≥20 岁，如果患者在随访 1 年内至少有这些疾病诊断要求，并且这些患者至少有 2 次门诊就诊或 1 次住院治疗。根据年龄、性别、合并症、药物和索引日期进行倾向匹配后，IMIDs 患者进入秋水仙碱使用者（n=16026）和秋水仙碱非使用者（n=16026）。此外，使用时间依赖性 Cox 模型分析了与非使用者相比，秋水仙碱使用者的癌症风险。使用 Cox 比例风险回归分析分析癌症累积发生率。我们计算了调整后的危险比（aHR）及其 95%置信区间（95%CI），用于调整性别、年龄、合并症和乙酰半胱氨酸、戒烟药物（尼古丁贴片和药丸）和药物、抗炎药和免疫抑制剂药物使用后癌症的发生。
与秋水仙碱非使用者相比，所有癌症风险均略有降低，所有癌症的（aHR（95%CI））为（0.84（0.55，0.99））。同时，秋水仙碱使用者与结直肠癌的发病率较低相关，（aHRs（95%CI））为（0.22（0.19，0.89））。年龄<65 岁和男性/女性的秋水仙碱使用者也与结直肠癌风险降低有关。此外，秋水仙碱使用>20 天与结直肠癌的较低 aHR 相关。
秋水仙碱与 IMIDs 患者的所有癌症和结直肠癌形成的 aHR 降低相关。
